News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Recognized by CIO Magazine as One of the CIO 100 Award Honorees

BOULDER, Colo.--(BUSINESS WIRE)--Jun. 2, 2009-- IDG's CIO magazine announced Array BioPharma Inc. (NASDAQ: ARRY) as a recipient of the 2009 CIO 100. The 22nd annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology (IT).

“This year's CIO 100 awards draws well-deserved attention to companies that are both innovating and creating business value with IT despite the economic downturn,” said Maryfran Johnson, Editor in Chief of CIO magazine & events. “These winners are an inspiration to businesses everywhere.”

“We are excited to be recognized for our cutting-edge IT capabilities,” said James Rizzi, Ph.D., Senior Director, Computational Technology. “We believe these capabilities provide Array with a competitive advantage over other biotech and pharmaceutical companies. Our recent initiative to expand our paperless research environment into the development and clinical arena was the basis for this recognition. In collaboration with Medidata Solutions and General Dynamics Viz, we have incorporated an innovative solution that provides our clinical scientists with real-time data that enables critical decision-making across our portfolio. Receiving this award validates not only our approach, but that we have achieved a solution that is unique in the industry.”

The 2009 CIO 100 awards will be presented at the Broadmoor in Colorado Springs, Colorado, on August 25 at the conclusion of the eleventh annual CIO 100 Symposium® and Awards Ceremony.

About the CIO 100

The recipients of this year's CIO 100 award were selected through a three-step process. First, companies filled out an online application form detailing their innovative practices in both business and IT. Next, a team of judges reviewed the applications in depth, looking for unique practices and substantial results. Finally, CIO editors reviewed the judges' recommendations and voted on the final 100. Once the top 100 honorees were selected, several honorees were chosen to receive an additional special award.

Complete coverage of the 2009 CIO 100 awards will be on www.cio.com after June 1, 2009 and in the August 1st issue of CIO magazine.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

About CIO Magazine

CIO produces award-winning content and community resources for information technology executives thriving and prospering in this fast-paced era of business, as well as create opportunities for information technology and consumer marketers to reach them. The CIO portfolio includes CIO.com, CIO magazine (launched in 1987), CIO Executive Programs and the CIO Executive Council. CIO properties provide business technology leaders with analysis and insight on information technology trends and a keen understanding of IT's role in achieving business goals. The U.S. edition of the magazine and website are recipients of more than 200 awards to date, including three Grand Neals from the Jesse H. Neal National Business Journalism Awards and two Magazine of the Year awards from the National Society of Business Publication Editors. CIO websites and magazines appear in more than 25 countries, including Australia, Canada, China, France and Germany. CIO, and sister brand CSO, are produced by CXO Media a subsidiary of International Data Group (IDG), the world's leading technology media, research and event company.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our future plans for advancing certain of our proprietary drug programs, the potential to earn future milestone payments, license fees or royalty revenue, and the plans of our collaborators to further develop drugs we have out-licensed or on which we are collaborating. These statements involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2008, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of June 2, 2009.

We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

Source: Array BioPharma

Array BioPharma
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com